Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Chidamide plus CHOP vs placebo plus CHOP in previously untreated PTCL-TFH
ChiCTR2500108138Phase 3Not yet recruiting
- Sponsor
- Union Hospital
- Start
- Apr 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in peripheral T-cell lymphoma (PTCL), angioimmunoblastic T-cell lymphoma (AITL), follicular T-cell lymphoma (FTCL) and 1 more comparing Chidamide + CHOP with Placebo + CHOP (2 arms). Primary endpoint: Progression-free survival (PFS). Planned start Apr 2025; status: not yet recruiting.
02
Drugs
tucidinostat
03
Conditions
peripheral T-cell lymphoma (PTCL)angioimmunoblastic T-cell lymphoma (AITL)follicular T-cell lymphoma (FTCL)T-cell lymphoma follicular helper (TFHL)
Beyond the preview
Go deeper on ChiCTR2500108138.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500108138.